Rosario Lopez-Pedrera

List of Publications by Year
in descending order

151 papers	3,840 citations	117625 34 h-index	144013 57 g-index
158 all docs	158 docs citations	158 times ranked	4955 citing authors

#	Article	IF	Citations
1	Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy. Annals of the Rheumatic Diseases, 2022, 81, 56-67.	0.9	18
2	The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast. Journal of Internal Medicine, 2022, 291, 676-693.	6.0	11
3	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. Arthritis and Rheumatology, 2021, 73, 1073-1085.	5.6	81
4	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. Journal of Rheumatology, 2021, 48, 541-547.	2.0	19
5	Characterization of Antiphospholipid Syndrome Atherothrombotic Risk by Unsupervised Integrated Transcriptomic Analyses. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 865-877.	2.4	11
6	Clinical Utility of microRNAs in Exhaled Breath Condensate as Biomarkers for Lung Cancer. Journal of Personalized Medicine, 2021, 11, 111.	2.5	13
7	NAD+ boosters reduce the oxidative, apoptotic and inflammatory status of leukocytes from rheumatoid arthritis patients. Free Radical Biology and Medicine, 2021, 165, 36.	2.9	0
8	Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis. Frontiers in Immunology, 2021, 12, 631662.	4.8	13
9	HLAâ€“B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Antiâ€“Carbamylated Protein Antibodyâ€“Positive/Antiâ€“Cyclic Citrullinated Peptideâ€“Negative Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 963-969.	5.6	12
10	Therapeutic Potential and Immunomodulatory Role of Coenzyme Q10 and Its Analogues in Systemic Autoimmune Diseases. Antioxidants, 2021, 10, 600.	5.1	17
11	Potential Role and Impact of Peripheral Blood Mononuclear Cells in Radiographic Axial Spondyloarthritis-Associated Endothelial Dysfunction. Diagnostics, 2021, 11, 1037.	2.6	1
12	Expression of DDX11 and DNM1L at the 12p11 Locus Modulates Systemic Lupus Erythematosus Susceptibility. International Journal of Molecular Sciences, 2021, 22, 7624.	4.1	2
13	Anti-dsDNA Antibodies Increase the Cardiovascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2417-2430.	2.4	29
14	Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs. Frontiers in Immunology, 2021, 12, 744022.	4.8	4
15	Subclinical cardiovascular risk signs in adults with juvenile idiopathic arthritis in sustained remission. Pediatric Rheumatology, 2020, 18, 59.	2.1	14
16	Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis. International Journal of Molecular Sciences, 2020, 21, 9067.	4.1	22
17	P92â€…Genomic convergence of locus-based GWAS meta-analysis identifies DDX11 as a novel systemic lupus erythematosus gene. , 2020, , .		0
18	O31â€…Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1

#	Article	IF	Citations
19	Complement component 3 as biomarker of disease activity and cardiometabolic risk factor in rheumatoid arthritis and spondyloarthritis. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232096506.	2.5	12
20	Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune Disorders. International Journal of Molecular Sciences, 2020, 21, 2012.	4.1	20
21	Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies. Haematologica, 2020, 105, 2250-2261.	3.5	20
22	Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients. Autoimmunity Reviews, 2020, 19, 102488.	5.8	5
23	Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF-Î± therapy effectiveness. Journal of Biomedical Science, 2020, 27, 54.	7.0	18
24	Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion. Journal of Cellular and Molecular Medicine, 2019, 23, 6308-6318.	3.6	15
25	Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1988074.	2.7	7
26	Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis. Frontiers in Immunology, 2019, 10, 1111.	4.8	20
27	New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches. Frontiers in Immunology, 2019, 10, 764.	4.8	30
28	THU0225â€…THE MOLECULAR PROFILING OF MONOCYTES FROM PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME IDENTIFIES SEVERAL NETWORKS RELATED TO THEIR ATHEROTHROMBOTIC STATUS. ROLE OF ANTIPHOSPHOLIPID ANTIBODIES ON MONOCYTE MIRNA SECRETION. , 2019, , .		0
29	AB0188â€…MOLECULAR NETWORKS IN MONOCYTES FROM SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS RELATED TO THEIR PHYSIOPATHOLOGY. MODULATORY EFFECTS OF ANTI-DSDNA ANTIBODIES AND MOLECULAR MECHANISMS UNDERLYING IN VIVOSTATIN TREATMENT. , 2019, , .		0
30	SAT0037â€…INCREASED CARDIOMETABOLIC RISK FACTORS ARE RELATED TO THE ABNORMAL ADIPOCYTOKINE PROFILE AND AUTOIMMUNITY IN RHEUMATOID ARTHRITIS. MODULATION BY TNFALPHA AND IL6R INHIBITORS. , 2019, , .		0
31	SAT0036â€…IMPACT OF RHEUMATOID ARTHRITIS IN LIVER DAMAGE. INVOLVEMENT OF ANTI-CITRULLINATED PROTEIN ANTIBODIES. , 2019, , .		0
32	AB0725â€…ASSOCIATION BETWEEN RADIOGRAPHIC PROGRESSION AND CARDIOVASCULAR RISK IN SPONDYLOARTHRITIS: DATA FROM COSPAR REGISTRY. , 2019, , .		0
33	OP0292â€…THE HELPFUL EIGHT: KEY SPLICING MACHINERY ELEMENTS IN LEUKOCYTE SUBSETS MAY IMPROVE THE TYPIFICATION OF THE DISEASE IN RHEUMATOID ARTHRITIS PATIENTS. , 2019, , .		0
34	AB0388â€…COMPARATIVE EFFECTIVENESS OF RITUXIMAB, TOCILIZUMAB AND TNFI BIOLOGICS IN RHEUMATOID ARTHRITIS PATIENTS. INFLUENCE OF CLINICAL AND INFLAMMATORY PROFILES. , 2019, , .		0
35	SAT0124â€…MOLECULAR CHARACTERIZATION OF THE SERUM PROFILE ASSOCIATED TO THE INCREASED CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS. EFFECTS OF BIOLOGICAL DRUGS.. , 2019, , .		0
36	Identification of a 3â€²â€‰Untranslated Genetic Variant of <scp>RARB</scp> Associated With Carotid Intimaâ€“Media Thickness in Rheumatoid Arthritis: A Genomeâ€“Wide Association Study. Arthritis and Rheumatology, 2019, 71, 351-360.	5.6	26

#	Article	IF	Citations
37	Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients. Human Molecular Genetics, 2018, 27, 875-890.	2.9	58
38	Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. Journal of Internal Medicine, 2018, 284, 61-77.	6.0	34
39	Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. Haematologica, 2018, 103, 908-918.	3.5	30
40	Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets. Autoimmunity Reviews, 2018, 17, 1138-1149.	5.8	88
41	<scp>VCE</scp>â€004.3, a cannabidiol aminoquinone derivative, prevents bleomycinâ€induced skin fibrosis and inflammation through PPARÎ³â€and CB₂ receptorâ€dependent pathways. British Journal of Pharmacology, 2018, 175, 3813-3831.	5.4	30
42	Regulation of TFPIÎ± expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens. Scientific Reports, 2017, 7, 43500.	3.3	20
43	Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. Journal of Autoimmunity, 2017, 82, 31-40.	6.5	82
44	Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Translational Research, 2017, 183, 87-103.	5.0	80
45	FRI0429â€…Dysregulation of the splicing machinery in leukocytes from ankylosing spondylitis patients is associated to disease pathogenesis. , 2017, , .		0
46	AB0104â€…Alterations of spliceosome components in leukocytes from patients with rheumatoid arthritis influence their autoimmune and inflammatory profile, and the development of cardiovascular disease. , 2017, , .		0
47	Mechanisms of atherosclerosis and cardiovascular disease in antiphospholipid syndrome and systemic lupus erythematosus. New therapeutic approaches. Medicina ClÃnica (English Edition), 2017, 149, 160-169.	0.2	3
48	Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?. Autoimmunity Reviews, 2017, 16, 1109-1114.	5.8	19
49	Mecanismos de aterosclerosis y enfermedad cardiovascular en el sÃndrome antifosfolÃpido y el lupus eritematoso sistÃ©mico. Alternativas terapÃ©uticas. Medicina ClÃnica, 2017, 149, 160-169.	0.6	3
50	AB0092â€…Effect of methotrexate, leflunomide and hydroxychloroquine on the insulin resistance and obesity associated with rheumatoid arthritis: obese mouse models of rheumatoid arthritis. , 2017, , .		0
51	AB0127â€…ANTI-DS-DNA antibodies regulate atherothrombosis in systemic lupus erythematosus through the induction of netosis, inflammation and endothelial activation. , 2017, , .		0
52	FRI0035â€…Specific monocyte subsets in patients with rheumatoid arthritis are associated with the progression of the disease along with their autoimmune and pro-atherothrombotic profile. , 2017, , .		0
53	Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1923-1932.	2.4	60
54	THU0218â€…Circulating micrornas as biomarkers for diagnosis and typifying the atherothrombotic status in antiphospholipid syndrome. , 2017, , .		0

#	Article	IF	Citations
55	AB0128â€…Alterations of the splicing machinery components in leukocytes from patients with systemic lupus erythematosus influences its development and atherothrombotic profile and drives the therapeutic response. , 2017, , .		0
56	FRI0069â€…Neutrophils play a key role in the regulation of the chronic inflammation associated with rheumatoid arthritis through epigenetic mechanisms modulated by anti-ccps antibodies and reversed by biologic therapies. , 2017, , .		0
57	FRI0048â€…The ANTI-CD20 antibody rituximab reduces the inflammatory and prothrombotic profile of leukocytes from rheumatoid arthritis patients and modulates the activity of endothelial cells. , 2017, , .		0
58	OP0336â€…Role of systemic inflammation associated with rheumatoid arthritis in the glucose and lipid metabolism: humans, cia mouse model and in vitro studies. , 2017, , .		0
59	FRI0360â€…Analysis of endocannabinoid system elements and related inflammatory molecules in peripheral blood leukocytes of patients with systemic sclerosis. , 2017, , .		0
60	FRI0431â€…Altered expression of circulating micrornas is related to disease activity and structural damage in ankylosing spondylitis patients. , 2017, , .		0
61	AB1130â€…Relapse risk assessment in young aps patients with previous stroke event using the adjusted global antiphospholipid syndrome score (AGAPSS). , 2017, , .		0
62	â€˜Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patientsâ€™. Scientific Reports, 2016, 6, 31375.	3.3	44
63	THU0243â€…Integrated Analysis of Microrna and MRNA Expression Profiles Related To Cardiovascular Disease in Monocytes from Systemic Lupus Erythematosus Patients. Annals of the Rheumatic Diseases, 2016, 75, 276.1-276.	0.9	0
64	THU0254â€…In Vivo Ubiquinol (COQ10) Supplementation Reduces The Atherothrombotic Status of Antiphospholipid Syndrome Patients. Annals of the Rheumatic Diseases, 2016, 75, 280.1-280.	0.9	0
65	OP0310â€…Association of Neutrophil Extracellular Traps with Atherosclerosis in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 175.1-175.	0.9	0
66	AB0104â€…Role of CD14+ and CD16+ Monocyte Subtypes in The Atherothrombosis Associated with Rheumatoid Arthritis: Epigenetic Mechanisms Involved. Annals of the Rheumatic Diseases, 2016, 75, 932.1-932.	0.9	0
67	FRI0046â€…TCZ Attenuates Atherothrombosis through The Specific Inhibition of Netosis and Monocyte-Mediated Proinflammatory Activity. Annals of the Rheumatic Diseases, 2016, 75, 442.3-443.	0.9	0
68	FRI0056â€…Altered Microrna Expression Pattern in Synovial and Blood Neutrophils in Rheumatoid Arthritis Reveals The Pathogenic Profile of These Cells. Annals of the Rheumatic Diseases, 2016, 75, 446.1-446.	0.9	0
69	AB0124â€…Peripheral Blood Mononuclear Cells from Ankylosing Spondylitis Patients Display An Atherogenic Profile Associated with Disease Activity and Endothelial Dysfunction. Annals of the Rheumatic Diseases, 2016, 75, 939.1-939.	0.9	0
70	THU0255â€…Identification of Novel Regulatory Networks Related To Atherothrombosis in Monocytes from Antiphospholipid Syndrome through Integrated Analysis of Microrna/mrna/protein Expression Profiles. Annals of the Rheumatic Diseases, 2016, 75, 280.2-280.	0.9	0
71	Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. Rheumatology, 2016, 55, 2096-2108.	1.9	59
72	Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. Rheumatology, 2016, 55, 1726-1735.	1.9	29

#	Article	IF	Citations
73	Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 601-610.	3.8	26
74	AB0133â€...Role of Monocytes Subsets in the Atherothrombosis and Endothelial Dysfunction Associated with Rheumatoid Arthritis: Beneficial Effects of Tocilizumab. Annals of the Rheumatic Diseases, 2015, 74, 935.2-935.	0.9	0
75	THU0398â€...Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial. Annals of the Rheumatic Diseases, 2015, 74, 340.3-341.	0.9	2
76	FRI0190â€...Role of Leukocyte Subsets in the Inflammation, Oxidative Stress and Bone Turnover in Ankylosing Spondylitis Patients. Annals of the Rheumatic Diseases, 2015, 74, 493.2-493.	0.9	0
77	AB0165â€...Regulation of Atherothrombosis in Systemic Lupus Erythematosus. Role of Different Monocyte Subsets, Netosis Involvement, and Effects of Anti-Dsdna Antibodies. Annals of the Rheumatic Diseases, 2015, 74, 945.3-946.	0.9	0
78	Simultaneous Inhibition of EGFR/VEGFR and Cyclooxygenase-2 Targets Stemness-Related Pathways in Colorectal Cancer Cells. PLoS ONE, 2015, 10, e0131363.	2.5	35
79	PXKlocus in systemic lupus erythematosus: fine mapping and functional analysis reveals novel susceptibility geneABHD6. Annals of the Rheumatic Diseases, 2015, 74, e14-e14.	0.9	24
80	Immunotherapy in antiphospholipid syndrome. International Immunopharmacology, 2015, 27, 200-208.	3.8	21
81	Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFÎ±. Arthritis Research and Therapy, 2015, 17, 49.	3.5	158
82	OP0156â€...In Vitro Treatment with Anti-Cardiolipin and Anti-DSDNA Antibodies Modifies the Expression of Micrornas Related to Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2015, 74, 128.1-128.	0.9	0
83	Increased Dihydroceramide/Ceramide Ratio Mediated by Defective Expression of degs1 Impairs Adipocyte Differentiation and Function. Diabetes, 2015, 64, 1180-1192.	0.6	55
84	Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Annals of the Rheumatic Diseases, 2015, 74, 1441-1449.	0.9	76
85	Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Annals of the Rheumatic Diseases, 2015, 74, 1450-1458.	0.9	49
86	CoCl2, a Mimic of Hypoxia, Induces Formation of Polyploid Giant Cells with Stem Characteristics in Colon Cancer. PLoS ONE, 2014, 9, e99143.	2.5	101
87	Anticyclic Citrullinated Protein Antibodies Are Implicated in the Development of Cardiovascular Disease in Rheumatoid Arthritis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2706-2716.	2.4	52
88	AB0188â€...Atherosclerosis and Cardiovascular Disease in Systemic Lupus Erythematosus. Effects of Statins Treatment. Annals of the Rheumatic Diseases, 2014, 73, 865.2-865.	0.9	0
89	Proteomic approaches to evaluate protein sâ€nitrosylation in disease. Mass Spectrometry Reviews, 2014, 33, 7-20.	5.4	51
90	OP0188â€...Circulating Mirnas as Potential Biomarkers of Therapy Effectiveness in Rheumatoid Arthritis Patients Treated with Anti-TNF. Annals of the Rheumatic Diseases, 2014, 73, 133.3-134.	0.9	1

#	Article	IF	Citations
91	THU0460â€…Charaterization of Micrornas Involved in the Regulation of Atherotrhombosis in Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2014, 73, 342.2-342.	0.9	0
92	FRI0167â€…Effect of Infliximab and Paricalcitol on Inflammation and Mineralization/Calcification of Mesenchymal Stem Cells during Osteogenic Differentiation. Annals of the Rheumatic Diseases, 2014, 73, 442.2-442.	0.9	0
93	The Future Potential of Biosimilars Targeting B-Cells. Milestones in Drug Therapy, 2014, , 277-284.	0.1	0
94	SAT0044â€…Anti-cyclic citrullinated protein antibodies induce inflammation and oxidative stress in monocytes and neutrophils of rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2013, 71, 485.3-485.	0.9	0
95	SAT0161â€…Fluvastatin treatment prevents the inflammatory/oxidative status linked to the clinical activity of the disease in systemic lupus erythematosus patients. Annals of the Rheumatic Diseases, 2013, 71, 526.2-526.	0.9	0
96	Cardiovascular Risk in Systemic Autoimmune Diseases: Epigenetic Mechanisms of Immune Regulatory Functions. Clinical and Developmental Immunology, 2012, 2012, 1-10.	3.3	38
97	Nitric Oxide and Cancer: The Emerging Role of S-Nitrosylation. Current Molecular Medicine, 2012, 12, 50-67.	1.3	92
98	Proteomics insights into deregulated proteinS-nitrosylation and disease. Expert Review of Proteomics, 2012, 9, 59-69.	3.0	8
99	Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood, 2012, 119, 5859-5870.	1.4	82
100	309 Maintenance of S-nitrosothiol Homeostasis Plays an Important Role in Growth Suppression in Estrogen Receptor Positive Breast Tumors. European Journal of Cancer, 2012, 48, S76.	2.8	0
101	713 Cyclooxygenase-2 Inhibition Enhances the Anti-tumoral Activity of the Multi-target Kinase Inhibitor AEE788 in Colorectal Cancer Cells. European Journal of Cancer, 2012, 48, S169.	2.8	0
102	Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors. Breast Cancer Research, 2012, 14, R153.	5.0	31
103	Catastrophic antiphospholipid syndrome (CAPS). Best Practice and Research in Clinical Rheumatology, 2012, 26, 535-541.	3.3	44
104	Progression from High Insulin Resistance to Type 2 Diabetes Does Not Entail Additional Visceral Adipose Tissue Inflammation. PLoS ONE, 2012, 7, e48155.	2.5	36
105	Potential Use of Statins in the Treatment of Antiphospholipid Syndrome. Current Rheumatology Reports, 2012, 14, 87-94.	4.7	28
106	To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer. Current Drug Targets, 2012, 13, 829-841.	2.1	16
107	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Thrombosis?. , 2012, , 57-78.		0
108	311 INFLAMMATION, LEUKOCYTE ACTIVATION, AND SURROGATE ATHEROSCLEROSIS MARKERS IN RHEUMATOID ARTHRITIS PATIENTS ARE RELATED TO MITOCHONDRIAL DEPOLARISATION AND OXIDATIVE STRESS. Atherosclerosis Supplements, 2011, 12, 67.	1.2	0

#	Article	IF	Citations
109	414 OXIDATIVE STRESS MEDIATES APL-INDUCED THROMBOSIS AND ATHEROSCLEROSIS DEVELOPMENT IN ANTIPHOSPHOLIPID SYNDROME. Atherosclerosis Supplements, 2011, 12, 89.	1.2	0
110	Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2011, 9, 1985-1992.	3.8	98
111	VEGF targeted therapy in acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2011, 80, 241-256.	4.4	30
112	Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2011, 70, 675-682.	0.9	82
113	ES936 stimulates DNA synthesis in HeLa cells independently on NAD(P)H:quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK. Chemico-Biological Interactions, 2010, 186, 174-183.	4.0	5
114	AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia. Experimental Hematology, 2010, 38, 641-652.	0.4	6
115	Differential expression of proteaseâ€activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis and Rheumatism, 2010, 62, 869-877.	6.7	52
116	Proteomics in antiphospholipid syndrome: a review. Lupus, 2010, 19, 385-388.	1.6	5
117	Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Role of Proinflammatory Cytokines and Therapeutic Approaches. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-13.	3.0	37
118	The obese healthy paradox: is inflammation the answer?. Biochemical Journal, 2010, 430, 141-149.	3.7	151
119	Pharmacological impairment of s-nitrosoglutathione or thioredoxin reductases augments protein S-Nitrosation in human hepatocarcinoma cells. Anticancer Research, 2010, 30, 415-21.	1.1	19
120	Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia. Experimental Hematology, 2009, 37, 679-691.	0.4	13
121	Novel biomarkers of atherosclerosis and cardiovascular risk in autoimmune diseases: Genomics and proteomics approaches. Proteomics - Clinical Applications, 2009, 3, 213-225.	1.6	10
122	VEGF/KDR loop is a target of AG1296 in acute myeloid leukaemia showing FLT3â€internal tandem duplications. British Journal of Haematology, 2009, 145, 836-838.	2.5	12
123	Use of povidoneâ€“iodine during the first trimester of pregnancy: a correct practice?. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 452-455.	2.3	15
124	Proteomic analysis in monocytes of antiphospholipid syndrome patients: Deregulation of proteins related to the development of thrombosis. Arthritis and Rheumatism, 2008, 58, 2835-2844.	6.7	55
125	MEK inhibition induces caspases activation, differentiation blockade and PML/RARÎ± degradation in acute promyelocytic leukaemia. British Journal of Haematology, 2008, 142, 27-35.	2.5	6
126	Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases. Lupus, 2008, 17, 905-916.	1.6	7

#	Article	IF	Citations
127	Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. Leukemia and Lymphoma, 2007, 48, 1187-1199.	1.3	15
128	Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematological Oncology, 2007, 25, 30-37.	1.7	34
129	Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets. Proteomics, 2006, 6, S293-S299.	2.2	60
130	Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2006, 4, 2461-2469.	3.8	85
131	Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia, 2006, 20, 1331-1340.	7.2	75
132	Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NFâ€ºB/Rel proteins via the p38 mitogenâ€activated protein kinase pathway, and of the MEKâ€1/ERK pathway. Arthritis and Rheumatism, 2006, 54, 301-311.	6.7	192
133	Antiphospholipid-Mediated Thrombosis: Interplay Between Anticardiolipin Antibodies and Vascular Cells. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 41-45.	1.7	17
134	Antiphospholipid syndrome and tissue factor: a thrombotic couple. Lupus, 2006, 15, 161-166.	1.6	32
135	Patogenia de la trombosis asociada a enfermedades neoplÃ¡sicas: implicaciones terapÃ©uticas. Medicina ClÃnica, 2004, 122, 190-196.	0.6	2
136	Promyelocytic leukemia retinoid signaling targets regulate apoptosis,tissue factor and thrombomodulin expression. Haematologica, 2004, 89, 286-95.	3.5	13
137	Antiphospholipid syndrome. Clinical and Experimental Medicine, 2003, 3, 129-139.	3.6	28
138	Regulation by Nitric Oxide of Endotoxin-Induced Tissue Factor and Plasminogen Activator Inhibitor-1 in Endothelial Cells. Thrombosis and Haemostasis, 2002, 88, 1060-1065.	3.4	29
139	The role of tissue factor in the antiphospholipid syndrome. Arthritis and Rheumatism, 2001, 44, 2467-2476.	6.7	48
140	Antithrombin III Prevents Early Pulmonary Dysfunction After Lung Transplantation in the Dog. Circulation, 2001, 104, 2975-2980.	1.6	30
141	Plasma thrombopoietin level after liver transplantation: relationship to cold ischemia time and coagulation parameters. Intensive Care Medicine, 2000, 26, 804-807.	8.2	3
142	A Modulatory Role for Substance P on the Regulation of Luteinizing Hormone Secretion by Cultured Porcine Gonadotrophs1. Biology of Reproduction, 1998, 58, 678-685.	2.7	19
143	C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog.. American Journal of Respiratory and Critical Care Medicine, 1997, 155, 1147-1154.	5.6	37
144	Elevated levels of tissue factor pathway inhibitor in acute non-lymphoblastic leukemia patients with disseminated intravascular coagulation. Blood Coagulation and Fibrinolysis, 1997, 8, 70-71.	1.0	11

#	Article	IF	Citations
145	Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte tissue factor expression. Arthritis and Rheumatism, 1997, 40, 834-841.	6.7	204
146	Characterization of tissue factor expression on the human endothelial cell line ECV304. , 1997, 56, 71-78.		17
147	Tissue Factor (TF) and Urokinase Plasminogen Activator Receptor (uPAR) and Bleeding Complications in Leukemic Patients. Thrombosis and Haemostasis, 1997, 77, 062-070.	3.4	18
148	Heterogeneity of growth hormone (GH)-producing cells in aging male rats: in vitro GH releasing activity of somatotrope subpopulations. Molecular and Cellular Endocrinology, 1996, 123, 127-137.	3.2	16
149	Monounsaturated Fatty Acidâ€“Enriched Diet Decreases Plasma Plasminogen Activator Inhibitor Type 1. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 82-88.	2.4	90
150	The effect of exogenous nitric oxide on plasminogen activator inhibitor in experimentally induced endotoxemia. Fibrinolysis, 1996, 10, 21-25.	0.5	2
151	Distinct Patterns of Urokinase Receptor (uPAR) Expression by Leukemic Cells and Peripheral Blood Cells. Thrombosis and Haemostasis, 1996, 76, 1009-1019.	3.4	34